Scholarlink

Background <p>Immune checkpoint inhibitors (ICIs) have shown significant effectiveness in cancer treatment, yet checkpoint inhibitor-related pneumonitis (CIP) remains a severe immune-related adverse event (irAE). This study conducts a bibliometric analysis to identify potential research directions for CIP associated with ICIs in cancer therapy.</p> Methods <p>We retrieved articles published from 1991 to 2024 in the Web of Science Core Collection (WoSCC) database. Bibliometric tools, including VOSviewer, R-bibliometrix, and CiteSpace, were employed to analyze publication trends, contributing countries, journals, authors, and keywords.</p> Results <p>A total of 673 publications were analyzed, with the United States, China, and Japan identified as the primary contributors. The Lancet Oncology was the leading journal in terms of article volume and impact factor. Jarushka Naidoo had the highest H-index and publication output among authors. Recent research has focused on enhancing ICI efficacy in lung cancer while minimizing safety risks associated with adverse events through various drug combinations and therapeutic modifications. Key areas of emphasis include expanding ICI applications beyond melanoma and non-small cell lung cancer (NSCLC), managing severe CIPs and pre-existing pulmonary conditions, integrating radiotherapy and chemoradiotherapy with immunotherapy, and exploring corticosteroids and immunosuppressants.</p> Conclusion <p>Although the number of clinical trials on ICIs is increasing, effective strategies for preventing CIP and managing its symptoms are still lacking, and international collaboration in this research area is limited. This analysis offers a comprehensive overview of the current landscape, highlighting emerging research trends and key areas for future investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Knowledge mapping and visualization of immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Yanyan Jiang,
  • Mingling Xu,
  • Shanlin Xu,
  • Qian Wu

摘要

Background

Immune checkpoint inhibitors (ICIs) have shown significant effectiveness in cancer treatment, yet checkpoint inhibitor-related pneumonitis (CIP) remains a severe immune-related adverse event (irAE). This study conducts a bibliometric analysis to identify potential research directions for CIP associated with ICIs in cancer therapy.

Methods

We retrieved articles published from 1991 to 2024 in the Web of Science Core Collection (WoSCC) database. Bibliometric tools, including VOSviewer, R-bibliometrix, and CiteSpace, were employed to analyze publication trends, contributing countries, journals, authors, and keywords.

Results

A total of 673 publications were analyzed, with the United States, China, and Japan identified as the primary contributors. The Lancet Oncology was the leading journal in terms of article volume and impact factor. Jarushka Naidoo had the highest H-index and publication output among authors. Recent research has focused on enhancing ICI efficacy in lung cancer while minimizing safety risks associated with adverse events through various drug combinations and therapeutic modifications. Key areas of emphasis include expanding ICI applications beyond melanoma and non-small cell lung cancer (NSCLC), managing severe CIPs and pre-existing pulmonary conditions, integrating radiotherapy and chemoradiotherapy with immunotherapy, and exploring corticosteroids and immunosuppressants.

Conclusion

Although the number of clinical trials on ICIs is increasing, effective strategies for preventing CIP and managing its symptoms are still lacking, and international collaboration in this research area is limited. This analysis offers a comprehensive overview of the current landscape, highlighting emerging research trends and key areas for future investigation.